EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Efficacy of tocilizumab monotherapy for autoimmune hemolytic anemia associated with idiopathic multicentric Castleman disease: a case-based review

Koji Suzuki, Mitsuhiro Akiyama, Koichi Saito, Kanako Shimanuki, Yuko Kaneko

Rheumatology International · 2025

DOI: 10.1007/s00296-025-05880-w ↗

Kurz gefasst

Fallbericht in der Zeitschrift Rheumatology International, 2025. Verfasst von Koji Suzuki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. Hauptthemen laut MEDLINE: Anemia, Hemolytic, Autoimmune, Antibodies, Monoclonal, Humanized, Castleman Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by generalized lymphadenopathy with distinctive histopathological features and systemic inflammation driven by excessive interleukin-6 (IL-6) production. Anemia due to chronic inflammation is a common manifestation of iMCD; however, this disease can also be complicated by autoimmune hemolytic anemia (AIHA). While tocilizumab (TCZ), an IL-6 receptor blockade, has demonstrated efficacy in treating iMCD, its therapeutic effect on AIHA secondary to iMCD remains unclear. Here, we report the first case of iMCD complicated by AIHA successfully treated with TCZ monotherapy, without the need for concurrent glucocorticoid therapy. Notably, AIHA improved along with the disappearance of autoantibodies under TCZ monotherapy, suggesting that IL-6 played a key role in the production of autoantibodies and causing AIHA secondary to iMCD. Furthermore, our literature review identified six other cases of iMCD with AIHA, five of which achieved favorable outcomes with a combination of TCZ and prednisolone, except for one case that developed anti-TCZ antibody. In two cases, AIHA improved without requiring an increase of prednisolone dose. These findings suggest that TCZ may represent a viable therapeutic option not only for iMCD itself but also for AIHA secondary to iMCD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Hemolytic, AutoimmuneAntibodies, Monoclonal, HumanizedCastleman DiseaseFemaleHumansMiddle AgedPrednisoloneTreatment Outcome

Stichwörter der Autor:innen

Autoimmune hemolytic anemiaInterleukin-6Multicentric Castleman diseaseTocilizumab

Substanzen

Antibodies, Monoclonal, HumanizedPrednisolonetocilizumab

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. ykaneko.z6@keio.jp.

Zitieren

APA

Suzuki, K., Akiyama, M., Saito, K., Shimanuki, K., & Kaneko, Y. (2025). Efficacy of tocilizumab monotherapy for autoimmune hemolytic anemia associated with idiopathic multicentric Castleman disease: a case-based review. Rheumatology International. https://doi.org/10.1007/s00296-025-05880-w

Vancouver

Suzuki K, Akiyama M, Saito K, Shimanuki K, Kaneko Y. Efficacy of tocilizumab monotherapy for autoimmune hemolytic anemia associated with idiopathic multicentric Castleman disease: a case-based review. Rheumatology International. 2025. doi:10.1007/s00296-025-05880-w

BibTeX
@article{Suzuki2025,
  author = {Suzuki, Koji and Akiyama, Mitsuhiro and Saito, Koichi and Shimanuki, Kanako and Kaneko, Yuko},
  title = {Efficacy of tocilizumab monotherapy for autoimmune hemolytic anemia associated with idiopathic multicentric Castleman disease: a case-based review},
  journal = {Rheumatology International},
  year = {2025},
  doi = {10.1007/s00296-025-05880-w}
}
Kostenlos starten →